for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amicus Therapeutics, Inc.

FOLD.O

Latest Trade

14.60USD

Change

0.68(+4.89%)

Volume

4,999,818

Today's Range

13.84

 - 

14.64

52 Week Range

6.25

 - 

16.13

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.92
Open
14.06
Volume
4,999,818
3M AVG Volume
46.91
Today's High
14.64
Today's Low
13.84
52 Week High
16.13
52 Week Low
6.25
Shares Out (MIL)
258.79
Market Cap (MIL)
3,602.33
Forward P/E
-14.63
Dividend (Yield %)
--

Next Event

Q3 2020 Amicus Therapeutics Inc Earnings Release

Latest Developments

More

Amicus Therapeutics Sees FY 2020 Revenue $250 Million To $260 Million

Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing

Amicus Therapeutics Announces First Quarter 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Industry

Biotechnology & Drugs

Contact Info

1 Cedarbrook Dr

CRANBURY, NJ

08512-3618

United States

+1.609.6622000

http://www.amicusrx.com

Executive Leadership

John F. Crowley

Chairman of the Board and Chief Executive Officer

Bradley Lewis Campbell

President, Chief Operating Officer, Director

Daphne E. Quimi

Chief Financial Officer

Samantha Whiteman Prout

Principal Accounting Officer, Vice President - Finance, Controller

Hung Viet Do

Chief Scientific Officer

Key Stats

1.62 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019

0.2K

2020(E)

0.3K
EPS (USD)

2017

-1.850

2018

-1.880

2019

-1.480

2020(E)

-0.998
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.87
Price To Book (MRQ)
9.96
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
41.57
LT Debt To Equity (MRQ)
41.57
Return on Investment (TTM)
-41.22
Return on Equity (TTM)
-36.18

Latest News

Latest News

BRIEF-Amicus Therapeutics Announces First Quarter 2020 Financial Results

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATES

BRIEF-Amicus Therapeutics Sees FY 2020 Revenue Of $250 Mln To $260 Mln

* AMICUS THERAPEUTICS ANNOUNCES FULL-YEAR 2019 FINANCIAL RESULTS AND 2020 CORPORATE UPDATES

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics <FOLD.O> on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES

BRIEF-Amicus Therapeutics Prices Underwritten Offering Of Common Stock

* AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK

BRIEF-Amicus Therapeutics Announces Public Offering Of Common Stock

* AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat

* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study

* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUM™

BRIEF-Amicus Launches Galafold For Treatment Of Fabry Disease In Spain

* AMICUS THERAPEUTICS LAUNCHES GALAFOLD™ (MIGALASTAT) FOR TREATMENT OF FABRY DISEASE IN SPAIN Source text for Eikon: Further company coverage:

BRIEF-Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln

* AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE

BRIEF-Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat

* AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

BRIEF-Amicus Therapeutics Q3 loss per share $0.69

* Amicus therapeutics announces third quarter 2017 financial results and corporate updates

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

BRIEF-Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society

* Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society

BRIEF-U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease

* U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease

BRIEF-Amicus Therapeutics announces approval for Galafold™ for treatment of Fabry disease in Canada

* Amicus Therapeutics Inc announces approval for Galafold™ (Migalastat) for treatment of Fabry disease in Canada

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up